Responders to treatment (at least 50% improvement, on MRS) were 50% of the ziprasidone group and 35% of the placebo group (P<0.05). Another 3-week

trial was newly positive for ziprasidone. Somnolence and extrapyramidal, symptoms were the most reported adverse events.73 A third monotherapy placebo-controlled trial also had a haloperidol arm, and http://www.selleckchem.com/products/BAY-73-4506.html showed significant superiority over placebo but lower efficacy versus haloperidol (up to 30 mg/day) at the 3-week and 12-week end points.52,74 Two hundred and five bipolar patients receiving lithium were part of a double -blind trial that studied ziprasidone as add-on treatment over 3 weeks. This trial failed to yield positive results. Somnolence, Inhibitors,research,lifescience,medical extrapyramidal symptoms, dizziness, and agitation were more frequent in the group Inhibitors,research,lifescience,medical receiving ziprasidone and lithium.75 Another potential side effect, of the drug is activation (some sort

of akathisia vs anxiety and restlessness). Further add-on controlled trials are currently ongoing with ziprasidone. Aripiprazole Aripiprazolc is a partial agonist Inhibitors,research,lifescience,medical of dopamine D2/D3and serotonin (5-HT)1Areceptors and an antagonist of 5-HT2Aand histamine H1receptors, and a moderate serotonin reuptake inhibitor. This agent demonstrated a superior response rate to haloperidol (50% vs 28.4%) in patients remaining on treatment in a 12-week comparative trial.76 Two hundred and sixty -two patients with an acute manic or mixed episode were randomized either to aripiprazole or placebo. They were Inhibitors,research,lifescience,medical hospitalized at least for 2 weeks and followed for an extra week. Aripiprazole significantly improved YMRS scores (-8.2 vs -3.4 for placebo; P<0.01) Response rate was significantly Dorsomorphin price higher too (40% versus 19%; P<0.01) The percentage of aripiprazole-treated patients achieving response was significantly higher than that of placebo-treated patients as early as day 4 (14% vs 5%; P<0.05) This was confirmed by a second 3-wcek

study. Akathisia was significantly higher with aripiprazole when compared with placebo.77,78 Another trial randomized manic patients to aripiprazole Inhibitors,research,lifescience,medical (n=175) or haloperidol (n=172). GSK-3 After 12 weeks, 50.9% of aripiprazole-treated patients and 29.1% of the haloperidol group responded to treatment. Greater tolerability for aripiprazole should be considered when discussing these data,51 because the definition of response included the capacity to stay in the trial until its end. There is only one very recent placebo-controlled trial with aripiprazole as adjunctive treatment of mood stabilizers, which showed better efficacy for the combination.79 Activation and akathisia have been reported with aripiprazole. Amisulpride Only one controlled trial is available for this drug in mania. A multicenter, open, randomized trial compared amisulpride with haloperidol in manic patients taking valproate.80 Amisulpride was not significantly superior to haloperidol, but.